期刊档案 · Medicine-Oncology
Asian Pacific Journal of Cancer Biology
ISSN 2538-4635 · West Asia Organization for Cancer Prevention · Iran, Islamic Republic of
Asian Pacific Journal of Cancer Biology 完全开放获取，APC 约 300 美元，投稿社区反馈审稿约 6 周，2025 年发文 69 篇，Scopus 收录。
研究范围
研究范围与定位
Asian Pacific Journal of Cancer Biology 由 West Asia Organization for Cancer Prevention 出版。按 OpenAlex 近年发文统计，该刊主要发表 Breast Cancer Treatment Studies、Cervical Cancer and HPV Research、Breast Lesions and Carcinomas 等主题的论文，这 3 个主题约占 22.7%，主导子领域为 Oncology。（根据 OpenAlex 主题统计与中科院分区数据生成）
The Asian Pacific Journal of Cancer Biology (APJCB) is an open-access electronic journal that covers all aspects of cancer research, including basic, preclinical, clinical, translational, molecular, epidemiological, prevention, therapy, and rehabilitation. It lays a strong grounding forum for Oncologists, physicians, General Surgeons, Gynecologists, Dermatologists, Gastroenterologists, Pulmonologists, Radiologists, Pathologists, Epidemiologists, and Researchers, as Cancer research is one of the most cited fields. The journal was launched in 2016 as the official publication of the Asian Pacific Organization for Cancer Prevention. All manuscripts published in the Asia Pacific Journal of Cancer Biology are under the terms of the Creative Commons Attribution License. This permits anyone to copy, distribute, transmit, and adapt the published work, provided the original work and source are appropriately cited. The Asian Pacific Journal of Cancer Biology's objective is to be a medium of information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research across Asia and the Pacific Region and internationally. It publishes original research articles, systematic and narrative literature reviews, clinical trial protocols, guest editorials, and letters to the Editor related to the basic science of cancer. The editor welcomes contributions from a wide spectrum of the basic science of cancer, especially in the fields of: Cancer genetics and personalized medicine Cancer and stem cell biology Molecular and clinical immunology Cancer prevention and epidemiology Cancer biomarkers Radiation and medical physics Oncology clinical trials Clinical Oncology Mechanisms of drug sensitivity and resistance Targeted therapy and immunotherapy Multidisciplinary treatment and The journal adheres to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for Medical Journal Editors (ICMJE).
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Medicine-Oncology
主编 Abas Ghaderi出版商官网
编委会国家分布：未见中国大陆编委；主要国家 伊朗 10、印度 4、日本 2、土耳其 2、埃及 2（共 30 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology10.2%
- Cervical Cancer and HPV ResearchMedicine6.3%
- Breast Lesions and CarcinomasMedicine6.1%
- Nanoparticle-Based Drug DeliveryMaterials Science5.9%
- Head and Neck Cancer StudiesMedicine5.9%
- Endometrial and Cervical Cancer TreatmentsMedicine4.1%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics4.1%
- Colorectal Cancer Treatments and StudiesMedicine4.1%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
CiteScore 分区（Scopus，2026 年 6 月版）
| 学科 | 分区 | 排名 | 百分位 |
|---|---|---|---|
| Oncology | Q3 | 298/428 | 30% |
| Cancer Research | Q4 | 193/233 | 17% |
| Cell Biology | Q4 | 262/289 | 9% |
Scopus 按 CiteScore 在每个学科内为期刊排名，百分位 75 及以上为 Q1，每 25 为一档；与中科院分区是不同体系。LetPub
数据库收录
ScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
Portico出版商官网
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- CiteScore 2026-06
- 1.9LetPub ·
- SJR 2026-06
- 0.32LetPub ·
- SNIP 2026-06
- 0.5LetPub ·
- h-index
- 15OpenAlex ·
- i10-index
- 30OpenAlex ·
- 两年平均被引
- 1.34OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
发文规模
- 年发文量（出版商公布）
- 2,017出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 430 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 89 | 89 | 244 |
| 2025 | 69 | 69 | 312 |
| 2024 | 62 | 62 | 212 |
| 2023 | 38 | 38 | 140 |
| 2022 | 38 | 38 | 190 |
| 2021 | 35 | 35 | 78 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度（社区反馈）
- 6 WeeksLetPub ·
- 投稿到发表（期刊自报）
- 约 6 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 300 | 无 | CC BY | |
| LetPub | 无文章处理费 | 无 | — | |
| 出版商官网 | 有，金额未公布 | — | — |
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
接收的文章类型10 种，含篇幅限制
- commentaries/ letter to editorCommentaries presents a point of view of general interest not related to an article in the same issue of the APJCB.未说明篇幅
- correspondenceLetters to the Editor or Correspondences are related to papers previously published in the APJCP. Letters must be submitted within six months of the online publ…正文 ≤ 750 词
- editorialEditorials: are the opinions of recognized leaders in cancer specialties. Editorials are generally solicited by the Editor-in-Chief and are related to a manuscr…正文 ≤ 2,400 词 · 参考文献 ≤ 20
- editorialsEditorials: are the opinions of recognized leaders in cancer specialties. Editorials are generally solicited by the Editor-in-Chief and are related to a manuscr…未说明篇幅
- methodological papersManuscripts containing a description of novel methods and significant improvements to tried-and-tested basic research techniques related to cancer are welcome. …未说明篇幅
- research articleorts of original research. The text for research articles is limited to 5,000 words including the title page, abstract, body of manuscript (Int正文 ≤ 5,000 词
- research articlesResearch Articles Scientific reports of original research. The text for research articles is limited to 5,000 words including the title page, abstract, body of …未说明篇幅
- short communicationShort Communications are brief notes on selected topics from recognized cancer organizations such as the Asian Pacific Organization for Cancer Prevention. The l…正文 ≤ 2,000 词 · 参考文献 ≤ 20
- short communicationsShort Communications are brief notes on selected topics from recognized cancer organizations such as the Asian Pacific Organization for Cancer Prevention. The l…未说明篇幅
- systematic review and meta-analysisSystematic Review and Meta-analysis: Systematic Review and Meta-analysis are essential to summarize evidence relating to any knowldge acuratly and and reliably.…未说明篇幅
官网政策摘录作者资格、数据可用性、出版伦理、许可与版权、开放获取
- 作者资格 APJCB Authorship Consideration and Dispute Management:
APJCB considers an author as a person who has substantially contributed to all stages of research that the manuscript reports its results. On the other hand, all authors who are listed in the manuscript have contributed to the research, and the manuscript was submitted to the journal. There are many different definitions of authorship among different bodies that oversee authorship rights and respo…
原文 ↗出版商官网 ·- 数据可用性
Privacy statement: names and emails used exclusively for stated journal purposes. 模型摘要
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
原文 ↗出版商官网 ·- 出版伦理 Publication Ethics
APJCB is very sensitive to research misconduct and uses all means available to prevent publishing miscounted research. Though there is no standard definition of research misconduct, the Council of Science Editors defines research misconduct broadly in three categories of action and conduct: Mistreatment of research subjects Falsification and Fabrication of Data Piracy and Plagiarism APJCB uses thi…
原文 ↗出版商官网 ·- 许可与版权 Copyright Notice
Copyright retained by West Asia Organization for Cancer Prevention; CC BY 4.0 license. 模型摘要
West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).
原文 ↗出版商官网 ·- 开放获取 Open Access Policy
Articles published in the Asian Pacific Journal of Cancer Biology are 'open access'. A universally accepted definition of the term is provided in the Bethesda Statement on Open Access Publishing in 2003: The article is universally and freely accessible via the Internet, in an easily readable format, and deposited immediately upon publication, without embargo, in a PDF format on the Journal's site …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- West Asia Organization for Cancer Prevention
- 出版国家或地区
- Iran, Islamic Republic of
- 出版语言
- English
- ISSN
- 2538-4635
- 学会 / 主办单位
- Asian Pacific Organization for Cancer Prevention
- 官网最新一期
- Volume 11, Issue 3（2026 年）
- 官方链接
- 期刊主页 ↗LetPub
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
常见问题
关于 Asian Pacific Journal of Cancer Biology 的常见问题
Asian Pacific Journal of Cancer Biology 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 6 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Asian Pacific Journal of Cancer Biology 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 30 位编委中，没有中国大陆学者；人数最多的国家是 伊朗（10 位）、印度（4 位）、日本（2 位）。统计按编委会页面列出的机构国家计，仅供参考。
Asian Pacific Journal of Cancer Biology 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Asian Pacific Journal of Cancer Biology 被 Scopus、DOAJ 收录。
Asian Pacific Journal of Cancer Biology 是开放获取期刊吗？版面费多少？
Asian Pacific Journal of Cancer Biology 为完全开放获取。APC 约 300 美元。
来源与更新
本页事实来自 LetPub、DOAJ、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。